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ABSTRACT:
Introduction: Apical Hypertrophic Cardiomyopathy (AHCM) is a unique variant with distinct clinical 
presentation, genetics, treatment, complications and outcome. Case: A 52 year non-hypertensive Asian 
male presented with exertional shortness of breath for two years without chest pain, palpitation or syncope. 
Apex beat was heaving. Electrocardiogram revealed non q wave deep symmetrical T wave inversion in 
anterolateral leads and echocardiography demonstrated hypertrophied apical septum. Coronary angiogram 
showed normal coronaries with typical “Ace of Spade” configuration during ventriculography. Conclusion: 
Characterization of various forms of hypertrophic cardiomyopathy is essential for management purpose as 
apical hypertrophic cardiomyopathy usually have benign course.   
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INTRODUCTION:
 First described by Sakamoto et al, Apical 
Hypertrophic Cardiomyopathy (AHCM) is an 
infrequent variant localized to apex of the heart.
[1] Yamaguchi et al. subsequently portrayed  its 
typical end systolic left ventriculogram pattern 
resembling “Ace of Spade”. Hence it is also 
known as Yamaguchi Disease.[2]  In Japanese 
population, it encompasses about 15% of all cases 
of hypertrophic cardiomyopathy,[1,2] however in 
non Japanese population it is only 1-3%.[3,4] It 
has dissimilar genetics, age distribution, clinical 
course, and complications compared to other 
forms of hypertrophic cardiomyopathy.[3,5,6] 
These attributes make AHCM an unique entity of 
discussion.
CASE REPORT:
 A 52 years diabetic gentleman with a 
body mass index of 24.5kg/m2, non-smoker, 
non-hypertensive presented to cardiac OPD with 
complaint of occasional shortness of breath on 
prolonged exertion for two years without orthopnoea 
or paroxysmal nocturnal dyspnoea. He denied any 
history of fever, cough, weight loss, chest tightness, 
noisy breathing, chest pain, palpitation, dizziness, 
excessive fatigability, pre-syncope, syncope or 
sleep related disorders. There was no past history 
of chest problem, cardiac disease, thyroid illness, 
neurological or hematological disorder. There was no 
family history of cardiac diseases. His diabetes had 
been on good control with anti-diabetes medications 
for last six years. Blood Pressure: 120/80 mm Hg, 
Heart Rate: 82/min regular, saturation: 100% in 
ambient air. There was no pallor or edema. Apex 
beat was localized at left 5th intercostal space 9cm 
from mid-sternal line and was heaving. 
 Other systemic examinations were 
unremarkable. Hematology, glycated hemoglobin, 
renal function test with electrolytes, creatinine 
phosphokinase (CPK-MB), troponin I and thyroid 
profile were normal. Chest X-ray was unremarkable. 
Electrocardiography (ECG)  showed non-q wave 
deep symmetrical T wave inversion in leads I, II, 
avl, V2-V6 with giant T wave inversion (1.0 mv) in 
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leads V3 and V4 (Fig. 1). 
Fig.1. ECG showing giant T wave inversion in 
precordial leads. 
 With such ECG findings, he underwent 
treadmill test multiple of times in past and all 
of them were negative and was advised for 
coronary angiography. Echocardiography revealed 
hypertrophic apical one-third of interventricular 
septum (17mm), normal aortic gradient, absent 
left ventricular outflow gradient, absence of 
intraventricular/apical mass with no regional/global 
wall motion abnormality (Fig. 2). 
 Coronary angiography showed normal 
epicardial coronary arteries with typical “Ace of 
Spades” configuration of left ventricle at end systole 
during ventriculography (Fig. 3). He was put on 
beta-blocker, advised for family screening including 
regular follow up examination.
 DISCUSSION:
 AHCM has two morphological forms: a) Pure 
Apical form: hypertrophy (>15mm) confined to left 
ventricular apex below the papillary muscle, and b) 
Distal Dominant form: apical hypertrophy extends 
to the interventricular septum without basal septal 
hypertrophy. Transition of AHCM to and from other 
forms of hypertrophic cardiomyopathy has not yet 
been documented.[7]
 Though genetic association is rare, some 
AHCM have familial association with autosomal 
dominant inheritance involving sarcomere gene 
mutation (cardiac actin Glu10Lys).[3,6,8,9] Patient 
may be asymptomatic or present with atypical 
chest pain, angina, palpitation, dyspnoea, pre/ 
syncope or cerebrovascular accident.[3,6,10] They 
may have hypertension, forceful apical beat with 
or without widely split second heart sound and or 
fourth heart sound.[6] Essential for diagnosis is 
typical ECG showing non-q deep (giant) T wave 
inversion, high QRS voltage over the precordial 
leads, intra ventricular conduction abnormalities or 
arrhythmias in the form of atrial fibrillation, supra 
ventricular tachycardia, non sustained ventricular 
tachycardia and even ventricular fibrillation[1,2,3,6] 
and can occur in following entities: a) Adams-
Fig. 2. Echocardiography: showing normal interventricular septum at base and hypertrophy of apex. 
Fig. 3. Left ventriculography showing normal diastolic 
flow and end systolic ace of spade configuration.
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Stokes attacks associated with complete heart block, 
b) ischemic heart disease, c) bradycardia, d) right 
ventricular hypertrophy and right bundle branch 
block, e) metabolic disturbances, f) changes during 
coronary angiography and g) cerebral disturbance.
[11] This giant T wave inversion is resultant of 
altered repolarisation changes of  hypertrophied 
apical musculature.[1] Echocardiography should 
also be performed with high degree of suspicion. 
Echocardiographic diagnostic criteria includes: a) 
asymmetric LV hypertrophy (LVH) predominantly 
at the apex of the ventricle; b) LV wall thickness 
of 15mm or more during diastole; and c) apical 
to posterior wall thickness ratio of 1.5 or more 
determined by two dimensional echocardiography.
[3] Use of intravenous echocardiographic contrast 
agents can be of help if apical endocardium is 
not visualized properly.[12] Echocardiography 
carries sensitivity of 91% for diagnosing AHCM.
[3] Angiography demonstrates no obstructive 
lesion. Hemodynamic studies display absence of 
pressure gradient in left ventricular outflow tract 
and complete systolic obliteration of the apex 
with relative sparing of ventricular cavity at base 
during left ventriculography forming the typical 
“Ace of Spade” configuration.[2] Cardiac Magnetic 
Resonance Imaging (CMRI) is decisive when there is 
suspicion of AHCM by ECG and echocardiographic 
feature is inconclusive or technically challenging. 
CMRI has the advantage of being less operator 
dependant, multi-planar detection and excellent soft 
tissue contrast.[13]
 Mimickers of AHCM and their diagnostic 
tools are listed below in the table.[14]
Disease Diagnostic tool to establish 
diagnosis of AHCM
Coronary artery 
disease
Echocardiogram/coronary 
angiogram and LVG
Left ventricular 
apical tumors
Echocardiogram with 
contrast/CCT/CMRI
Left ventricular 
apical thrombus
Echocardiogram with 
contrast/CCT/CMRI
Isolated ventricular 
non-compaction
CMRI/CCT
Endomyocardial 
fibrosis
LVG/CMRI
AHCM: Apical hypertrophic cardiomyopathy; 
CMRI: Cardiac magnetic resonance imaging; LVG: 
Left ventriculography; CCT: Cardiac computed 
tomography.
 Treatment of symptomatic patient constitutes 
beta blocker, verapamil and anti-arrhythmic agents. 
Amiodarone and procainamide are used for atrial 
fibrillation and ventricular arryhthmias.[3,15,16,17] 
Implantable Cardioverter Defibrillator (ICD) 
is recommended in patient who have survived 
a cardiac arrest due to ventricular tachycardia, 
ventricular fibrillation or who have spontaneous 
sustained ventricular tachycardia causing syncope 
or hemodynamic compromise.[18] 
 Long term follow up studies depict AHCM 
as benign entity with 15 year survival of 95% and 
annual cardiovascular mortality of 0.1%- 0.8%.
[3,19] Predictors for cardiovascular comorbidity[3] 
includes a) age at presentation < 41 years, b) 
left atrial enlargement and c) New York Heart 
Association functional class II or more at baseline 
and that for cardiovascular mortality18 includes a) 
LV outflow obstruction, b) atrial fibrillation and c) 
female gender. Almost one third of patients (30%) 
can develop serious cardiovascular complication 
of atrial fibrillation and myocardial infarction.[3] 
Hence periodic lifelong follow up should be initiated 
even for asymptomatic patient.[20]
CONCLUSION:
 Coronary artery disease, aortic stenosis 
and hypertension should be ruled out in every 
case presenting with such symptoms and 
electrocardiographic and/or echocardiographic 
presentation before designating a diagnosis of 
hypertrophic cardiomyopathy. Moreover, specifying 
the types of hypertrophic cardiomyopathy is 
important as apical hypertrophic cardiomyopathy 
carries benign prognosis compared to other variants.
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